Bienville Capital Management LLC lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 195.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,274 shares of the medical instruments supplier’s stock after acquiring an additional 2,166 shares during the period. Bienville Capital Management LLC’s holdings in Becton, Dickinson and were worth $639,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of BDX. Almanack Investment Partners LLC. purchased a new position in Becton, Dickinson and during the first quarter worth about $105,000. Parkside Financial Bank & Trust boosted its holdings in Becton, Dickinson and by 1.4% during the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 9 shares during the last quarter. QCI Asset Management Inc. NY boosted its holdings in Becton, Dickinson and by 9.2% during the first quarter. QCI Asset Management Inc. NY now owns 710 shares of the medical instruments supplier’s stock worth $130,000 after purchasing an additional 60 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its holdings in Becton, Dickinson and by 55.8% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 670 shares of the medical instruments supplier’s stock worth $131,000 after purchasing an additional 240 shares during the last quarter. Finally, Financial Architects Inc boosted its holdings in Becton, Dickinson and by 8.0% during the second quarter. Financial Architects Inc now owns 731 shares of the medical instruments supplier’s stock worth $142,000 after purchasing an additional 54 shares during the last quarter. 87.12% of the stock is owned by institutional investors.

Becton, Dickinson and Company (BDX) opened at 195.00 on Thursday. The stock has a market capitalization of $44.37 billion, a PE ratio of 56.47 and a beta of 1.05. The firm has a 50-day moving average of $197.37 and a 200-day moving average of $192.32. Becton, Dickinson and Company has a 1-year low of $161.29 and a 1-year high of $206.63.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same period in the previous year, the business posted $2.35 earnings per share. The business’s revenue for the quarter was down 5.1% on a year-over-year basis. Equities analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 29th. Stockholders of record on Friday, September 8th were paid a $0.73 dividend. The ex-dividend date of this dividend was Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.50%. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

Several research firms recently weighed in on BDX. Barclays PLC restated an “equal weight” rating and set a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a report on Thursday, August 10th. BidaskClub cut shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies restated a “buy” rating and set a $213.00 price target on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Stifel Nicolaus restated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Finally, Zacks Investment Research cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, August 7th. Five analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $200.93.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/bienville-capital-management-llc-acquires-2166-shares-of-becton-dickinson-and-company-bdx/1609281.html.

In other news, insider Gary M. Cohen sold 15,512 shares of Becton, Dickinson and stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the sale, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares of the company’s stock, valued at $5,279,917.98. The disclosure for this sale can be found here. Insiders sold 75,904 shares of company stock valued at $15,242,688 over the last quarter. Company insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.